Natco Pharma's management expects better FY28 with traction coming from Canada, Brazil and India besides some niche launches in the US which can translate into 15- 25 per cent PAT growth.
Market Samachar is a news aggregator. This article was originally published by Markets. Tap the button above to read the full story on their site.